<DOC>
	<DOCNO>NCT02726269</DOCNO>
	<brief_summary>The goal trial compare non-inferiority efficacy safety two different treatment scheme : pantoprazole 80 mg + levofloxacin 500 mg + azithromycin 500 mg daily ( PLA , test ) vs. clarithromycin 500 mg + lansoprazole 30 mg + amoxicillin 1 g twice daily ( CLA , reference ) , 10 day , Helicobacter Pylori ( HP ) eradication . Both scheme test treatment-naive patient , biopsy-based diagnosis HP infection . One month finish treatment , C13-urea breath testing require verify HP eradication . Biopsies also take identify Clarithromycin-resistance mutation HP strain fluorescence situ hybridization ( FISH ) .</brief_summary>
	<brief_title>Triple Therapy Versus Levofloxacin-based Therapy Helicobacter Pylori Eradication Mexico .</brief_title>
	<detailed_description>This phase IIIb study prospective , open-label , randomize , parallel-group , non-inferiority efficacy safety trial . It carry four outpatient clinic two city place Mexico ( Mexico City town Toluca ) . The study approve central Ethics Committee COFEPRIS ( Mexican Federal Commission Sanitary Risks Protection ) conduct accordance Helsinki Declaration protection human subject Good Clinical Practice guideline . Two hundred thirty subject age 18 65 year , HP infection proven endoscopic biopsy treatment-naïve include study signing inform consent . They randomly allocate one two group : Group 1 receive clarithromycin 500 mg twice daily ( bid ) , amoxicillin 1 g bid , lansoprazole 30 mg bid ( Pylopac® , Medix SA de CV , Mexico ) ; Group 2 receive azithromycin 500 mg daily ( od ) ( Truxa® , Laboratorios Monte Verde SA , Argentina ) , levofloxacin 500 mg od ( Laboratorios Asofarma de México SA de CV , Mexico ) , pantoprazole 80 mg od ( Zoltum® , Laboratorio Monte Verde SA , Argentina ) . Both group receive treatment 10 day . Antibiotics prescribed meal , whereas proton-pump inhibitor take fasting condition . No medication allow end treatment . Subjects evaluate use 13C-urea breath test ( 13C-UBT ) four week HP eradication treatment . Eradication H. pylorus define negative 13C-UBT . No medication allow four week precede 13C-UBT . Regarding safety assessment , blood sample collect central laboratory follow signature inform consent treatment begin . An additional blood sample drawn end treatment group comparison initial result . Patient compliance treatment-related AEs assess end treatment ( except whether AE serious , case report immediately appropriate action decide time ) . All biopsy review central pathologist . Endoscopic biopsy immediately fix 10 % buffer formalin , embed paraffin , section ( 4 mm slice thickness ) , dehydrated series increase ethanol/xylol concentration . Each section stain hematoxylin eosin ( H &amp; E ) . The diagnosis gastritis establish accordance updated Sydney system10 . Fluorescent situ hybridization ( FISH ) perform biopsy . Briefly , formalin-fixed paraffin-embedded 4-mm tissue section spot onto slide coat poly-L-lysine process hexane ethanol . Hybridization do use commercially available BACTfish H pylorus combi kit ( Izinta Trading Co. Ltd. , Hungary ) . The probe H. pylorus identification ( Hpy 1 ) ( 5'CACACCTGACTGACTATCCCG-3 ' ) label fluorescein isothiocyanate ( FITC ) provide green signal , probe detect three prevalent clarithromycin-resistance mutation ( ClaR1 ( A2143G ) 5'CGGGGTCTTCCCGTCTt-3 ' , ClaR2 ( A2144G ) 5'CGGGGCTCTCCGTCTT-3 ' , ClaR3 ( A21443C ) 5-CGGGGTCTTGCCGTCTT-3 ' ) label red fluorochrome ( Cy3 ) . Following hybridization 90 minute 46 °C , section wash wash buffer twice 46 °C 15 minute . Air-dried section stain 4 ' , 6 ' diamino-2-phenylindole ( DAPI ) . Slides evaluate use fluorescence Nikon Eclipse 80i microscope . Pictures take Nikon DS-Fi1 camera process NIS-Elements 2.1 software . Continuous variable describe use mean standard deviation . Efficacy analysis base H. pylori eradication rate subject finish treatment per protocol . Considering non-inferiority approach , Group 2 consider inferior Group 1 upper limit 95 % confidence interval ( CI ) difference eradication rate group low pre-established non-inferiority margin δ = 0.12 % . Such margin select accordance previously publish trial perform reference combination . Chi-square test Student 's t-test use compare group regard baseline data , eradication rate , adverse event biochemical result safety analysis . P value &lt; 0.05 consider significant . IBM SPSS 21 use perform statistical analysis .</detailed_description>
	<mesh_term>Gastritis</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>1 . Male female adult subject wish participate sign inform consent . 2 . Aged 18 65 year . 3 . HP infection diagnose endoscopic gastric biopsy . 4 . Subjects fulfill follow HP eradication criterion accord Maastricht 3 Consensus Report : Non ulcer dyspepsia gastric biopsy positive HP infection , Uncomplicated duodenal ulcer ( without active bleeding , perforation stenosis ) gastric biopsy positive HP infection , Uncomplicated benign gastric ulcer ( without active bleeding , perforation stenosis ) gastric biopsy positive HP infection , Chronic intake NSAIDs gastric biopsy positive HP infection without active gastrointestinal bleeding . 1 . Pregnant lactating woman . 2 . Subjects previously receive PLA CLA treatment . 3 . Subjects diagnose endoscopy upper gastrointestinal bleeding secondary active peptic ulcer ( gastric duodenal ) injury classify follow stage Forrest Classification : Ia ( Spurting hemorrhage ) , Ib ( Oozing hemorrhage ) , IIa ( Visible vessel ) IIb ( Adherent clot ) . 4 . Subjects diagnose endoscopy upper gastrointestinal bleed erosive gastritis secondary active NSAID positive biopsy HP infection whose clinical condition require hospitalization / blood transfusion . 5 . Subjects psychiatric disorder include eat disorder . 6 . Subjects chronic degenerative disease include uncontrolled hepatic , renal endocrine disease ( except diabetes control oral hypoglycemic agent control hypothyroidism ) , malabsorption chronic diarrhea , history seizure epilepsy , gastric surgery subject oncological disease . 7 . Subjects previous allergic reaction treatment component : Pantoprazole , Amoxicillin , Clarithromycin , Azithromycin Levofloxacin . 8 . Subjects history photosensitivity tendinitis secondary quinolones intake . 9 . Subjects take following medication : NSAIDS : Fenbufen ergot Oral anticoagulant Cyclosporine Digoxin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Helicobacter Pylory infection</keyword>
	<keyword>Levofloxacin</keyword>
	<keyword>Antibiotic resistance</keyword>
	<keyword>Clarithromycin</keyword>
	<keyword>Mutations</keyword>
	<keyword>Fluorescence</keyword>
	<keyword>Hybridization</keyword>
</DOC>